Changes in the concentrations of mediators in exhaled breath condensate during cardiac valve replacement under cardiopulmonary bypass and their relations with postoperative acute respiratory distress syndrome.
Adult
Aged
Aged, 80 and over
Cardiopulmonary Bypass
/ adverse effects
Case-Control Studies
Exhalation
Female
Heart Valve Prosthesis Implantation
/ adverse effects
Humans
Interleukin-6
Interleukin-8
Length of Stay
Male
Middle Aged
Postoperative Period
Prospective Studies
Respiratory Distress Syndrome
/ etiology
Tumor Necrosis Factor-alpha
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
22 May 2020
22 May 2020
Historique:
entrez:
3
6
2020
pubmed:
3
6
2020
medline:
20
6
2020
Statut:
ppublish
Résumé
To investigate the changes in the concentrations of interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), and 8-iso-prostaglandin F2α (8-isoPGF2α) in exhaled breath condensate (EBC) in patients undergoing cardiac valve replacement under cardiopulmonary bypass (CPB) and its relationship with postoperative acute respiratory distress syndrome (ARDS).A prospective, case-control study was performed on 55 patients undergoing elective cardiac valve replacement under cardiopulmonary bypass, between November 2017 and May 2019. According to the diagnosis of postoperative ARDS, the patients were divided into ARDS group and control group. We compared the clinical characteristics, outcomes, respiratory mechanics, oxygenation parameters, and mediators in the 2 groups immediately after tracheal intubation (T1), at the end of CPB (T2), and 2 hours (T3) and 6 hours (T4) after CPB, and calculated the receiver operating characteristic curve (ROC), sensitivity, and specificity of the corresponding mediators.ARDS occurred in 29 patients after CPB. The ARDS group exhibited prolonged postoperative ventilator support, time to extubation, length of stay in the ICU, and postoperative length of stay. The peak airway pressure (Ppeak) and plat airway pressure (Pplat) at T4 were higher in the ARDS group compared with the control group. The alveolar-arterial oxygen partial pressure [P(A-a)O2] and respiratory index (RI) were higher and PaO2/FiO2 was lower in the ARDS group at T2-4 compared with the control group. The levels of EBC and serum mediators in the ARDS group were significantly higher at T2-4 compared with those in the control group. All the mediators in EBC were correlated significantly with those in the serum in the ARDS group (r = 0.7314, 0.898, 0.8386, 0.792) and control group (r = 0.6093, 0.8524, r = 0.7828, r = 0.6575) (P < .001). Meanwhile, the area under the curve (AUC) of IL-8 in EBC was significantly lower at T2 and the AUC of IL-6 in EBC was significantly higher at T4 than in serum (P < .05). In addition, all of the mediators in EBC had a certain accuracy in diagnose of postoperative ARDS.EBC analysis could be used to predict the high incidence of ARDS after cardiac valve replacement under CPB.
Identifiants
pubmed: 32481266
doi: 10.1097/MD.0000000000020007
pii: 00005792-202005220-00021
pmc: PMC7249883
doi:
Substances chimiques
CXCL8 protein, human
0
Interleukin-6
0
Interleukin-8
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e20007Références
Immunopharmacol Immunotoxicol. 2019 Apr;41(2):224-230
pubmed: 31046512
J Biol Regul Homeost Agents. 2016 Jan-Mar;30(1):263-70
pubmed: 27049101
BMJ Open. 2018 Sep 10;8(9):e021408
pubmed: 30206081
PLoS One. 2014 Apr 14;9(4):e94124
pubmed: 24732309
Exp Ther Med. 2019 Mar;17(3):2099-2106
pubmed: 30867697
Exp Ther Med. 2018 Sep;16(3):1747-1752
pubmed: 30186397
BMC Pulm Med. 2015 Mar 14;15:22
pubmed: 25888398
Springerplus. 2016 Feb 29;5:231
pubmed: 27026925
Respir Care. 2015 May;60(5):679-88
pubmed: 25628453
Respir Med. 2018 Apr;137:134-140
pubmed: 29605196
Arch Pathol Lab Med. 2016 Apr;140(4):345-50
pubmed: 27028393
Springerplus. 2015 Oct 24;4:641
pubmed: 26543775
Turk J Med Sci. 2015;45(5):1073-7
pubmed: 26738349
Int J Gen Med. 2016 Nov 11;9:415-418
pubmed: 27956843
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
J Clin Lab Anal. 2017 Nov;31(6):
pubmed: 27957762
J Thorac Dis. 2016 Oct;8(10):E1177-E1186
pubmed: 27867583
BMC Anesthesiol. 2014 Aug 07;14:67
pubmed: 25126004
Paediatr Respir Rev. 2019 Feb;29:37-41
pubmed: 29921519
Eur Rev Med Pharmacol Sci. 2016;20(1):180-7
pubmed: 26813472
Brain Res. 2017 Feb 15;1657:377-382
pubmed: 28048971